The beat on EPS and raised full-year guidance indicate sustained operational leverage. With gross margins expanding and international momentum strong (EMEA +20%, APAC +18%), watch for further upside to estimates. The stock should react positively in the near term.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $110.22entry
- T+1 · 6mo ago −2.10%α −1.76% · $107.91
- T+5 · 6mo ago −11.79%α −12.93% · $97.22
- T+20 · 6mo ago −16.86%α −19.64% · $91.64
- T+60 · 4mo ago −8.07%α −10.14% · $101.32
Price Chart
How similar events traded
Executive Summary
LeMaitre Vascular reported Q1 2026 EPS of $0.68 (+42% YoY), a 3% beat on consensus of $0.66, on revenue of $66.6M (+11% YoY, in line with $66.7M consensus). The company raised full-year 2026 guidance: operating income midpoint increased to $79.8M (from $77.8M) and EPS to $3.00 (from $2.91), implying 24% adjusted EPS growth. Gross margin expanded 350 bps to 72.7%, and all product lines and geographies posted record sales.
Key Financial Metrics
Key Facts
- Q1 2026 EPS $0.68 beat consensus ($0.66) by 3.0%
- Q1 sales $66.6M (+11% YoY, +10% organic), in line with guidance midpoint
- Gross margin 72.7% (+350 bps YoY); operating margin 27% (+570 bps)
- Full-year 2026 guidance raised: revenue $277M–$283M (midpoint $280M, +12%), EPS $2.93–$3.08 (midpoint $3.00, +19%/+26% adjusted)
- Artegraft grew 36% worldwide; all three geographies posted record sales
Financial Impact
EPS beat of $0.02 vs consensus; guidance raised by $0.09 at midpoint
Risk Factors
- Revenue slightly below consensus by ~$0.15M (0.2% miss) may be noted by some
- Currency headwinds impacted reported sales by ~$2M in Q1
- Guidance assumes no further macroeconomic deterioration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-206578 |
| Document: d94324d8k.htm | 0001193125-26-206578 |
| Document: 0001193125-26-206578-index-headers.html | 0001193125-26-206578 |
| Document: 0001193125-26-206578-index.html | 0001193125-26-206578 |
| Document: 0001193125-26-206578.txt | 0001193125-26-206578 |
| 8-K Data (Synthetic) | 0001193125-26-206578 |
Track record
14 reports on LMAT
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.08% at T+20 after the May 7, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bearish 6/10 Entry $83.49 to $77.65 Now $77.01 +7.76% ▲ +6.99% +10.29% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $80.60 to $79.02 Now $77.01 −4.45% ▼ −1.96% −1.37% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $80.82 to $84.45 Now $77.01 −4.71% ▲ +4.49% +4.40% vs SPY
- Aug 27, 202611w ago Press Release Neutral 2/10 Entry $80.45 to $80.67 Now $77.01 −4.28% ▲ +0.27% +0.16% vs SPY
- Jul 14, 202617w ago Press Release Neutral 1/10 Entry $99.79 Now $77.01 −22.83% No price data
- May 7, 202627w ago Insider Cluster Bearish 4/10 Entry $107.91 to $98.17 Now $77.01 +28.63% ▲ +9.03% +10.53% vs SPY
- May 7, 202627w ago Insider Cluster Neutral 2/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
- May 7, 202627w ago Insider Cluster Neutral 3/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Viewing Entry $110.22 to $97.22 Now $77.01 −30.13% ▼ −11.79% −12.93% vs SPY
- Apr 14, 202630w ago DEFA14A Neutral 3/10 Entry $117.39 to $111.90 Now $77.01 −34.40% ▼ −4.68% −6.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers